Atlas Venture Life Science Advisors, LLC Q2 2022 Filing

Filed August 3, 2022

Portfolio Value

$598.2B

Holdings

16

Report Date

Q2 2022

Filing Type

13F-HR

All Holdings (16 positions)

#	Stock	Shares	Value	% Portfolio	Type
1	DAWNDay One Biopharmaceuticals, Inc.	8,968,305	$160.5B	26.84%
2	KYMRKymera Therapeutics, Inc.	6,875,698	$135.4B	22.63%
3	DYNDyne Therapeutics, Inc.	8,934,902	$61.4B	10.26%
4	REPLReplimune Group, Inc.	3,209,627	$56.1B	9.38%
5	GBIOGBXGeneration Bio, Co.	8,278,876	$54.3B	9.08%
6	AVTEAerovate Therapeutics, Inc.	2,638,297	$41.2B	6.89%
7	—Ikena Oncology, Inc.	5,018,178	$22.2B	3.72%
8	AKROAkero Therapeutics, Inc.	2,232,251	$21.1B	3.53%
9	VIGLVigil Neuroscience, Inc.	5,836,874	$15.1B	2.52%
10	—Gemini Therapeutics, Inc.	5,254,365	$8.9B	1.48%
11	XLOXilio Therapeutics, Inc.	2,759,344	$8.1B	1.35%
12	—Magenta Therapeutics, Inc.	3,476,536	$4.2B	0.70%
13	—AvroBio, Inc.	4,520,863	$4.2B	0.70%
14	—F-star Therapeutics, Inc.	599,524	$3.8B	0.63%
15	VRDNViridian Therapeutics, Inc.	90,072	$1.0B	0.17%
16	SPROSpero Therapeutics, Inc.	1,031,160	$764.0M	0.13%